Imricor Medical Financials
IMR Stock | 1.16 0.06 5.45% |
Operating Margin (19.77) | EPS Estimate Current Year (0.07) | Return On Equity (2.75) |
Imricor | Select Account or Indicator |
Understanding current and past Imricor Medical Financials, including the trends in assets, liabilities, equity and income are directly related to making proper and timely investing decisions. All of Imricor Medical's financial statements are interrelated, with each one affecting the others. For example, an increase in Imricor Medical's assets may result in an increase in income on the income statement.
Please note, the imprecision that can be found in Imricor Medical's accounting process means that the reasonable investor should take a skeptical approach toward the financial statement analysis of Imricor Medical Systems. Check Imricor Medical's Beneish M Score to see the likelihood of Imricor Medical's management manipulating its earnings.
Imricor Medical Stock Summary
Imricor Medical competes with Tombador Iron, Vulcan Steel, Ironbark Capital, Champion Iron, and Bluescope Steel. Imricor Medical is entity of Australia. It is traded as Stock on AU exchange.Foreign Associate | Poland |
Specialization | Health Care, Health Care Equipment & Services |
Instrument | Australia Stock View All |
Exchange | Australian Securities Exchange |
ISIN | AU0000054942 |
Business Address | 400 Gateway Boulevard, |
Sector | Health Care Equipment & Supplies |
Industry | Health Care |
Benchmark | Dow Jones Industrial |
Website | www.imricor.com |
Phone | 952 818 8400 |
You should never invest in Imricor Medical without having analyzed its financial statements. Do not rely on someone else's analysis or guesses about the future performance of Imricor Stock, because this is throwing your money away. Analyzing the key information contained in Imricor Medical's financial statements can give you an edge over other investors and help to ensure that your investments perform well for you.
Imricor Medical Key Financial Ratios
Imricor Medical's financial ratios allow both analysts and investors to convert raw data from Imricor Medical's financial statements into concise, actionable information that can be used to evaluate the performance of Imricor Medical over time and compare it to other companies across industries.Revenue | 615.57 K | ||||
Gross Profit | (1.53 M) | ||||
EBITDA | (21.87 M) | ||||
Net Income | (34.09 M) | ||||
Total Asset | 8.31 M |
Imricor Medical Key Balance Sheet Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Total Assets | 10.5M | 33.6M | 26.9M | 13.7M | 8.3M | 15.9M | |
Other Current Liab | 388.6K | 503.2K | 175.3K | 23.4K | 3.9M | 4.1M | |
Other Liab | 592.9K | 617.2K | 509.6K | 536.9K | 483.2K | 459.0K | |
Net Tangible Assets | 7.0M | 28.8M | 22.4M | 7.5M | 8.6M | 8.3M | |
Net Debt | (4.9M) | (23.8M) | (16.8M) | (1.2M) | 9.6M | 10.1M | |
Retained Earnings | (40.4M) | (52.9M) | (72.6M) | (90.0M) | (165.0M) | (156.7M) | |
Accounts Payable | 541.0K | 529.1K | 686.7K | 259.3K | 2.1M | 2.2M | |
Cash | 5.0M | 25.1M | 18.5M | 5.7M | 831.5K | 789.9K | |
Other Assets | 1.0M | 969.2K | 754.7K | 565.2K | (3.9M) | (3.7M) | |
Long Term Debt | 2.3M | 9.6M | 0.0 | 2.2M | 8.6M | 4.5M | |
Long Term Debt Total | 1.1M | 668.3K | 226.7K | 2.2M | 2.0M | 2.0M | |
Capital Surpluse | 47.4M | 81.7M | 95.0M | 97.5M | 112.1M | 59.6M | |
Inventory | 1.2M | 3.1M | 2.6M | 2.3M | 1.7M | 1.6M | |
Other Current Assets | 287.8K | 491.6K | 1.5M | 3.2M | 2.6M | 2.7M | |
Total Liab | 3.5M | 4.8M | 4.5M | 6.2M | 17.1M | 17.9M | |
Total Current Assets | 6.8M | 28.9M | 22.7M | 9.7M | 5.8M | 5.5M | |
Short Term Debt | 127.3K | 198.0K | 518.7K | 867.2K | 667.9K | 376.4K | |
Common Stock | 47.5M | 81.7M | 95.0M | 97.5M | 24.8K | 23.5K | |
Net Receivables | 256.3K | 223.2K | 94.7K | 125.5K | 392.6K | 412.2K | |
Net Invested Capital | 10.0M | 37.4M | 22.4M | 9.7M | 227.9K | 216.5K | |
Capital Stock | 47.5M | 81.7M | 95.0M | 97.5M | 103.8M | 86.7M | |
Net Working Capital | 7.7M | 34.6M | 20.0M | 7.6M | (628.2K) | (596.8K) |
Imricor Medical Key Income Statement Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Interest Income | 800.7K | 38.0K | 16.7K | 108.0K | 63.0K | 59.9K | |
Interest Expense | 1.0M | 300.6K | 108.8K | 177.9K | 47.9K | 45.5K | |
Total Revenue | 639.7K | 702.2K | 696.3K | 816.0K | 615.6K | 608.2K | |
Gross Profit | 262.3K | (397.7K) | (1.9M) | (1.5M) | (2.0M) | (1.9M) | |
Operating Income | (12.0M) | (11.6M) | (19.6M) | (17.2M) | (17.6M) | (18.5M) | |
Ebit | (12.0M) | (11.6M) | (19.9M) | (17.5M) | (22.6M) | (21.4M) | |
Research Development | 3.6M | 5.5M | 9.7M | 7.9M | 7.9M | 6.6M | |
Ebitda | (11.7M) | (11.1M) | (18.9M) | (16.5M) | (21.9M) | (20.8M) | |
Income Before Tax | (13.3M) | (12.4M) | (19.7M) | (17.4M) | (34.1M) | (32.4M) | |
Net Income | (14.8M) | (13.1M) | (20.6M) | (17.5M) | (22.6M) | (21.5M) | |
Income Tax Expense | 4.0 | 1.5M | 630.3K | 823.6K | 177.9K | (3.8) |
Imricor Medical Key Cash Accounts
2019 | 2020 | 2021 | 2022 | 2023 | 2024 (projected) | ||
Change To Inventory | (1.2M) | (2.7M) | (241.6K) | (641.9K) | (1.4M) | (1.3M) | |
Change In Cash | 3.5M | 20.1M | (6.6M) | (12.8M) | (4.9M) | (4.6M) | |
Net Borrowings | 3.2M | (382.4K) | (581.3K) | 2.0M | 1.8M | 1.6M | |
Free Cash Flow | (7.0M) | (13.0M) | (18.1M) | (17.1M) | (13.1M) | (13.7M) | |
Depreciation | 370.2K | 767.1K | 918.1K | 712.5K | 1.3M | 1.4M | |
Other Non Cash Items | 12.9M | 7.0M | 8.4M | 1.4M | 10.4M | 6.0M | |
Capital Expenditures | 364.8K | 741.9K | 625.7K | 238.9K | 82.8K | 78.6K | |
Net Income | (19.1M) | (18.1M) | (26.3M) | (17.5M) | (34.1M) | (32.4M) | |
End Period Cash Flow | 5.0M | 25.1M | 18.5M | 5.7M | 831.5K | 789.9K | |
Change To Netincome | 2.7M | 1.0M | 1.9M | 1.0M | 1.2M | 1.3M |
Imricor Financial Ratios Relationships
Comparative valuation techniques use various fundamental indicators to help in determining Imricor Medical's current stock value. Our valuation model uses many indicators to compare Imricor Medical value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Imricor Medical competition to find correlations between indicators driving Imricor Medical's intrinsic value. More Info.Imricor Medical Systems is currently regarded as number one stock in return on equity category among its peers. It also is currently regarded as number one stock in return on asset category among its peers . The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Imricor Medical's earnings, one of the primary drivers of an investment's value.Imricor Medical Systems Systematic Risk
Imricor Medical's systematic risk plays a vital role in portfolio allocation when considering its stock to be added to a well-diversified portfolio. Imricor Medical volatility which cannot be eliminated through diversification, requires returns over the risk-free rate. Over the long run, a well-diversified portfolio provides returns that match its exposure to systematic risk. In this case, investors face a trade-off between expected returns and systematic risk and, therefore, can only reduce a portfolio's exposure to systematic risk by sacrificing expected returns on the portfolio.
The output start index for this execution was thirty-six with a total number of output elements of twenty-five. The Beta measures systematic risk based on how returns on Imricor Medical Systems correlated with the market. If Beta is less than 0 Imricor Medical generally moves in the opposite direction as compared to the market. If Imricor Medical Beta is about zero movement of price series is uncorrelated with the movement of the benchmark. if Beta is between zero and one Imricor Medical Systems is generally moves in the same direction as, but less than the movement of the market. For Beta = 1 movement of Imricor Medical is generally in the same direction as the market. If Beta > 1 Imricor Medical moves generally in the same direction as, but more than the movement of the benchmark.
Imricor Medical Systems Total Assets Over Time
Imricor Medical Thematic Clasifications
Imricor Medical Systems is part of Drugs investing theme. If you are a theme-oriented, socially responsible, and at the same time, a result-driven investor, you can align your investing habits with your values without jeopardizing your expectations about returns. You can easily create an optimal portfolio of stocks, ETFs, funds, or cryptocurrencies based on a specific theme of your liking. Drug manufacturing and delivery. Companies involved in medical and pharmaceutical drug research, manufacturing, and delivery
This theme covers Drug manufacturing and delivery. Companies involved in medical and pharmaceutical drug research, manufacturing, and delivery. Get More Thematic Ideas
Drugs | View |
Imricor Medical December 2, 2024 Opportunity Range
Along with financial statement analysis, the daily predictive indicators of Imricor Medical help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Imricor Medical Systems. We use our internally-developed statistical techniques to arrive at the intrinsic value of Imricor Medical Systems based on widely used predictive technical indicators. In general, we focus on analyzing Imricor Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Imricor Medical's daily price indicators and compare them against related drivers.
Downside Deviation | 4.19 | |||
Information Ratio | 0.2177 | |||
Maximum Drawdown | 30.01 | |||
Value At Risk | (6.49) | |||
Potential Upside | 10.0 |
Additional Tools for Imricor Stock Analysis
When running Imricor Medical's price analysis, check to measure Imricor Medical's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Imricor Medical is operating at the current time. Most of Imricor Medical's value examination focuses on studying past and present price action to predict the probability of Imricor Medical's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Imricor Medical's price. Additionally, you may evaluate how the addition of Imricor Medical to your portfolios can decrease your overall portfolio volatility.